Source: yahoo_news
Source ID: yahoo:0059eaefc94409994015cdf3a89f5a9d:IMVT
URL: https://finance.yahoo.com/healthcare/articles/roivant-announces-topline-results-proof-110000478.html?.tsrc=rss
Symbol: (IMVT)
Published: 2026-09-23 07:00:00 EDT
Time precision: minute
Title: Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140